Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.
In this Review, we examine the concurrent outbreaks of mpox in Africa, focusing on clade 1a, the newly emerged clade 1b, and clade 2b lineage A, and how they differ from the 2022 global outbreak ...